Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Peptide and Oligonucleotide CDMO Market

Peptide and Oligonucleotide CDMO Market Trends

  • Report ID: GMI8502
  • Published Date: Mar 2024
  • Report Format: PDF

Peptide and Oligonucleotide CDMO Market Trends

  • Growing adoption of personalized medicine is a key driver propelling the peptide and oligonucleotide contract development and manufacturing organization (CDMO) market. Peptides and oligonucleotides play crucial roles in personalized medicine, as they can be designed to target specific genes, proteins, or pathways involved in diseases.
  • The U.S.FDA has approved several personalized medicines based on peptides and oligonucleotides. For instance, in 2022, five TIDES (four peptides and one oligonucleotide) were authorized by the FDA, including Vutrisiran (AmvuttraTM) for treating polyneuropathy of hereditary transthyretin-mediated amyloidosis and Gadopiclenol (EluciremTM) for detecting lesions with abnormal vascularity in the central nervous system and body.
  • Additionally, in 2020, six peptides and oligonucleotides were approved such as Viltolarsen (ViltepsoTM) for Duchenne’s muscular dystrophy and Lumasiran (OxlumoTM) for primary hyperoxaluria type 1.
  • As a result, pharmaceutical and biotechnology companies are increasingly outsourcing the development and manufacturing of peptides and oligonucleotides to specialized CDMOs to capitalize on their expertise and capabilities in this field.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of peptide and oligonucleotide CDMO was reached USD 2.3 billion in 2023 and is set to grow at a 12.1% CAGR from 2024 to 2032, driven by the increasing demand for personalized medicine and targeted therapies, requiring customized peptides and oligonucleotides.

Peptide and oligonucleotide CDMO from the peptide segment generated USD 1.5 billion in revenue in 2023 and is estimated to witness high demand through 2032, attributed to the increasing demand for peptide-based drugs in oncology, metabolic disorders, and infectious diseases.

North America peptide and oligonucleotide CDMO industry accounted for 44.9% revenue share in 2023 and is projected to reach USD 2.8 billion by 2032, owing to the presence of well-established pharmaceutical and biotechnology industries, advanced healthcare infrastructure, and strong regulatory framework.

Some of the top peptide and oligonucleotide CDMO companies are Aurigene Pharmaceutical Services Ltd., Bachem Group, CordenPharma International, Creative Peptides, Curia Global, Inc., EUROAPI S.A., Merck KGaA, PolyPeptide Group, STA Pharmaceutical Co. Ltd., and Sylentis, S.A.

Peptide and Oligonucleotide CDMO Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 237
  • Countries covered: 19
  • Pages: 135
 Download Free Sample